Ponatinib
- Medicine Name: Iclusig
- API: Ponatinib
- Dosage Form & Strength: Tablets: 10 mg/15 mg/30 mg/45 mg
- Manufactured By: Ariad Pharmaceuticals, Inc.
Medical Uses
- Iclusig (ponatinib) is a kinase inhibitor indicated for the treatment of adult patients with:
- Chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least a couple of prior kinase inhibitors.
- Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated.
- T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL.
Recommended Dosage:
CP-CML: The recommended starting dose of Iclusig is 45 mg orally with or without food once daily with a reduction to 15 mg orally once daily upon achievement of molecular response (≤1% BCR-ABL1IS). Those with loss of response can re-escalate the dose to a previously tolerated dosage of 30 mg or 45 mg orally once daily. Continue therapy until loss of response at the re-escalated dose or unacceptable toxicity. Consider discontinuing treatment in case a hematologic response has not occurred by three months.
AP-CML, BP-CML, and Ph+ ALL: The recommended starting dosage is 45 mg once daily with or without food. Continue therapy until loss of response or unacceptable toxicity. Consider reducing the dose for patients with accelerated phase (AP) CML who have achieved a major cytogenetic response. Consider discontinuing treatment in case a response has not occurred in three months.
Warning & Precautions
- AOEs, including fatalities, occurred in Ponatinib-treated patients. Monitor for the existence of AOEs. Interrupt or stop treatment with Ponatinib 15 mg/45 mg tablets immediately in case of an AOE. Consider benefit-risk to guide a decision to re-initiate the treatment.
- Venous thromboembolic events (VTEs) occurred in patients treated with oral Ponatinib. Cases of pulmonary embolism have been noted, some of which were fatal. Monitor for evidence of VTEs. Interrupt or stop treatment promptly in case of a VTE.
- Heart failure (some fatal), including left ventricular dysfunction and ejection fraction decrease, occurred in Ponatinib-treated patients. Monitor for signs or symptoms persistent with heart failure and treat as clinically required. Interrupt or stop therapy in those who develop new or worsening critical heart failure.
- Hemorrhage events (some fatal), including intracranial hemorrhage, hemorrhagic gastritis, and hemorrhagic cerebral infarction occurred in Ponatinib-treated patients. Most hemorrhagic events, but not all, developed in all those with grade 3/4 thrombocytopenia. Interrupt or stop treatment in those with critical or severe hemorrhage.
- Hepatotoxicity (including fatal acute hepatic failure) has been noted. Monitor hepatic function before and during treatment. Interrupt or stop Ponatinib therapy in patients with hepatotoxicity.
- Myelosuppression (thrombocytopenia, neutropenia, and anemia) has been reported in patients treated with this therapeutic drug. Myelosuppression was managed by withholding Ponatinib 15 mg or 45 mg temporarily or reducing the dose.
Documentation & Availability
What documents are required to import ICLUSIG to India?
ICLUSIG (ponatinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is ICLUSIG available in India?
ICLUSIG (ponatinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Iclusig (ponatinib) in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
ICLUSIG can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of ICLUSIG (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Iclusig tablet price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
Indian Pharma Network is able to source the ICLUSIG (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Iclusig®?
Ponatinib is a Generic Name for the trade name drug Iclusig®.
What is the Manufacturer’s Name of Iclusig®?
Iclusig® is manufactured by Ariad Pharmaceuticals, Inc.
Is Iclusig® approved by the FDA?
Yes, Iclusig® is approved by the FDA. Date of first approval: December 14, 2012.
Where can I get Iclusig® (ponatinib) at the best price in India?
To get the best Ponatinib price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Iclusig®, a medical prescription is needed from a treating physician.
What is the dosage and form of Iclusig® supplied?
Iclusig® is supplied as Tablets: 10 mg, 15 mg, 30 mg, and 45 mg for oral administration.
What are the most common side effects of Iclusig®?
The most common side effects of Iclusig® are abdominal pain, rash, arthralgia, headache, constipation, dry skin, hypertension, fatigue, fluid retention, pyrexia, nausea, pancreatitis/lipase elevation, anemia, hemorrhage, hepatic dysfunction, and AOEs.
How much does Iclusig® cost in India?
The cost of Iclusig (Ponatinib) in India can vary. To procure this kinase inhibitor legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Iclusig®?
Store the tablets of Iclusig® at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).
Is it safe to buy Iclusig® online in India?
Yes, one can buy Iclusig (Ponatinib) online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Iclusig® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
